BIOPHTA’s new standard of care offers a non-invasive, 7‑day topical microdosing, to provide a continuous therapeutic exposure for replacing injections or daily eyedrops. This scalable platform offers a transformative solution to poor adherence, burden and pain of injections, as well as inconsistent outcomes.